Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 6,455,542 | 5,838,755 | 5,906,221 | 5,791,947 | 5,635,655 |
| Depreciation Amortization | 881,360 | 848,584 | 600,133 | 483,346 | 474,480 |
| Accounts receivable | -432,330 | -318,687 | -400,751 | 10,481 | -705,701 |
| Accounts payable and accrued liabilities | -98,201 | -59,660 | 175,223 | -60,912 | 161,082 |
| Other Working Capital | -666,880 | 364,257 | 313,292 | -169,520 | 53,347 |
| Other Operating Activity | 1,819,403 | 339,374 | 227,669 | 198,077 | 1,560,597 |
| Operating Cash Flow | $7,958,893 | $7,012,622 | $6,821,787 | $6,253,419 | $7,179,460 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | N/A | 305,167 | 306,710 |
| PPE Investments | -891,318 | -1,338,307 | -1,471,357 | -1,157,022 | -1,049,265 |
| Net Acquisitions | N/A | -450 | 56,267 | N/A | N/A |
| Purchase Of Investment | -60,054 | -67,005 | -37,919 | -6,076 | -75,489 |
| Sale Of Investment | 1,838 | 22,185 | 27,216 | 11,089 | -16,643 |
| Purchase Sale Intangibles | -2,490,419 | -344,620 | -424,145 | -155,242 | -178,171 |
| Other Investing Activity | -2,487,661 | -341,622 | -421,239 | -151,293 | -174,307 |
| Investing Cash Flow | $-3,437,195 | $-1,725,199 | $-1,847,032 | $-998,135 | $-1,008,994 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 870,482 | -111,076 | 14,373 | N/A | N/A |
| Debt Repayment | -145,540 | N/A | N/A | N/A | N/A |
| Common Stock Repurchased | -2,582,186 | -2,298,567 | -2,380,194 | -2,558,756 | -2,237,470 |
| Dividend Paid | -3,082,537 | -2,909,409 | -2,912,439 | -2,862,404 | -3,541,138 |
| Other Financing Activity | 0 | 0 | -1 | 1 | 0 |
| Financing Cash Flow | $-4,939,781 | $-5,319,052 | $-5,278,261 | $-5,421,159 | $-5,778,608 |
| Exchange Rate Effect | -69,859 | -1,049 | 6,728 | -32,051 | -3,864 |
| Beginning Cash Position | 2,360,965 | 2,342,787 | 2,623,458 | 2,804,226 | 2,355,310 |
| End Cash Position | 1,873,023 | 2,310,109 | 2,389,674 | 2,606,300 | 2,743,305 |
| Net Cash Flow | $-487,942 | $-32,678 | $-233,784 | $-197,926 | $387,995 |
| Free Cash Flow | |||||
| Operating Cash Flow | 7,958,893 | 7,012,622 | 6,821,787 | 6,253,419 | 7,179,460 |
| Capital Expenditure | -892,390 | -1,338,907 | -1,473,344 | -1,158,389 | -1,050,305 |
| Free Cash Flow | 7,066,503 | 5,673,715 | 5,348,443 | 5,095,030 | 6,129,155 |